Winthrop Advisory Group LLC Has $218,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Winthrop Advisory Group LLC reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 350 shares of the company’s stock after selling 27 shares during the quarter. Winthrop Advisory Group LLC’s holdings in IDEXX Laboratories were worth $218,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. CHICAGO TRUST Co NA acquired a new position in shares of IDEXX Laboratories in the second quarter worth $1,730,000. Aviva PLC increased its position in IDEXX Laboratories by 11.2% in the 2nd quarter. Aviva PLC now owns 34,286 shares of the company’s stock worth $21,653,000 after purchasing an additional 3,464 shares during the last quarter. FMR LLC increased its position in IDEXX Laboratories by 3.1% in the 2nd quarter. FMR LLC now owns 941,474 shares of the company’s stock worth $594,588,000 after purchasing an additional 28,742 shares during the last quarter. Penobscot Wealth Management purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $3,069,000. Finally, Marshall Wace LLP lifted its holdings in shares of IDEXX Laboratories by 61.3% during the 2nd quarter. Marshall Wace LLP now owns 34,178 shares of the company’s stock valued at $21,584,000 after buying an additional 12,985 shares during the last quarter. Institutional investors own 84.89% of the company’s stock.

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 6,310 shares of the firm’s stock in a transaction dated Tuesday, November 9th. The shares were sold at an average price of $630.22, for a total transaction of $3,976,688.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Kathy V. Turner sold 276 shares of IDEXX Laboratories stock in a transaction on Friday, August 27th. The shares were sold at an average price of $678.00, for a total value of $187,128.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,836 shares of company stock worth $5,710,061. 2.06% of the stock is owned by company insiders.

Shares of IDXX traded up $2.47 during mid-day trading on Thursday, hitting $622.45. The company’s stock had a trading volume of 442,800 shares, compared to its average volume of 396,361. The stock’s 50-day moving average is $637.76 and its two-hundred day moving average is $633.83. The firm has a market capitalization of $52.78 billion, a PE ratio of 71.30, a price-to-earnings-growth ratio of 3.17 and a beta of 0.93. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.07 and a current ratio of 1.48. IDEXX Laboratories, Inc. has a one year low of $443.14 and a one year high of $706.95.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, November 2nd. The company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.88 by $0.15. IDEXX Laboratories had a net margin of 24.14% and a return on equity of 106.60%. The firm had revenue of $810.42 million during the quarter, compared to the consensus estimate of $793.26 million. During the same period in the prior year, the firm earned $1.69 EPS. Analysts expect that IDEXX Laboratories, Inc. will post 8.38 EPS for the current fiscal year.

A number of analysts have issued reports on IDXX shares. TheStreet cut shares of IDEXX Laboratories from a “b” rating to a “c+” rating in a research note on Tuesday, November 2nd. Barclays lifted their price objective on shares of IDEXX Laboratories from $616.00 to $750.00 and gave the company an “overweight” rating in a research note on Monday, August 2nd. Credit Suisse Group upped their price objective on shares of IDEXX Laboratories from $735.00 to $770.00 and gave the stock an “outperform” rating in a report on Friday, August 13th. Morgan Stanley started coverage on IDEXX Laboratories in a research report on Thursday, November 18th. They issued an “overweight” rating and a $732.00 price target for the company. Finally, The Goldman Sachs Group upped their price target on IDEXX Laboratories from $550.00 to $610.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 3rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $658.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management.

Read More: Cost of Capital

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.